Avadel Pharmaceuticals Announces Publication Of RESTORE Data Highlighting Challenges With Twice-Nightly Oxybates And Strong Patient Preference For Once-Nightly LUMRYZ Dosing Extended-Release Oral Suspension

Author: Benzinga Newsdesk | September 03, 2024 08:21am

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –

 

– 91% reported being better able to sleep through the night after switching to LUMRYZ –

– 93% of those who switched to LUMRYZ would recommend it to family or friends living with narcolepsy –

DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option. The U.S. Food and Drug Administration approved LUMRYZ in 2023 as the first and only once-nightly oxybate, which marked a significant milestone for people with narcolepsy, as twice-nightly oxybates were the only other oxybate options available for more than 20 years.

The paper, titled "RESTORE: Once-Nightly Oxybate Dosing Preference and Nocturnal Experience With Twice-Nightly Oxybates," was published online in Sleep Medicine: X. Initial and end-of-study survey data from RESTORE were previously presented in April 2022 at the American Academy of Neurology Annual Meeting and in June 2024 at SLEEP 2024.

Posted In: AVDL